*Nocardia takedensis* was first isolated from soil in 2005 \[[@CR1]\]. The first isolation in human was reported in 2006 in Japan \[[@CR2]\]. Since then, five cases of cutaneous Nocardiosis caused by *N. takedensis* have been described during a seven-year period (2010--2017): one in the US \[[@CR3]\], one in Mexico \[[@CR4]\], two in Asia \[[@CR5], [@CR6]\] and one in France \[[@CR7]\] (Table [1](#Tab1){ref-type="table"}). We report two cases of lymphangitis caused by *N. takedensis* both occurring after skin injury while gardening. The patients were both immunocompromised and living in Southeast France. We discuss the source of contamination, the global dissemination of this *Nocardia* species, and the measures to prevent infection.Table 1Main features of reported cases of human infections caused by *N. takedensis*AuthorsSex/age (years)Underlying conditions(s)Immunosuppression (risk factors)Type of infectionTreatmentInoculationGeographical origin of the strainMethods of identificationEvolutionWatanabe et al. \[[@CR2]\]M/75T-lymphomaYes (T-lymphoma)NANANAJapanSequencing 16S rRNA geneNABetran et al. \[[@CR13]\]F/41DiabetesEosinophilic granulomaYes (corticosteroid, diabetes)Lung colonizationNANASpainSequencing 16S rRNA geneNATan et al. \[[@CR5]\]F/68DiabetesChronic kidney diseaseYes (diabetes, chronic kidney disease)Foot cellulitisTrimethoprim-SulfamethoxazoleUnknownTaiwanSequencing 16S rRNA geneRecoveryKresch-Tronik et al. \[[@CR4]\]M/33NANAThoracic mycetomaTrimethoprim-Sulfamethoxazole (800/160 mg/b.i.d) and Dapsone (100 mg/day)---14 monthsLocal traumatic injuryMexicoSequencing 16S rRNA geneRecoveryChung et al. \[[@CR3]\]F/68Follicular lymphomaMyelodysplastic syndromeYes (corticosteroid, immunosuppressive treatment with sirolimus)Lymphangitis of the left forearmCefuroxime (500 mg/b.i.d)---7 daysAmoxicillin-clavulanate (875 mg/b.i.d)---14 daysTrimethoprim-Sulfamethoxazole (800/160 mg/b.i.d)---7 daysAbrasion on the left dorsal handUSASequencing 16S rRNA geneRecoveryCoussement et al. \[[@CR15]\]NASolid organ transplantYes (solid organ transplant)NANANAFranceSequencing 16S rRNA and *hsp65* genesNAGeun Lee et al. \[[@CR6]\]F/87Arterial hypertensionNoErythematous and swollen plaque on her left forearmPustules, abscesses, ulcersTrimethoprim-Sulfamethoxazole (400/80 mg/b.i.d)---40 daysAbrasion on the left forearmKoreaSequencing 16S rRNA geneRecoveryBenzaquen et al. \[[@CR7]\]M/76Marginal zone lymphomaDiabetesArterial hypertensionYes (corticosteroid, immunosuppressive treatment with chloraminophene and rituximab, diabetes)Chronic ulcerative suppurative and painful nodules on the right forearmRifampicin (600 mg/day)---3 monthsClarithromycin (500 mg/b.i.d)---6 monthsEthambutol (800 mg/day)---6 monthsSkin traumaFranceSequencing 16S rRNA geneRecoveryLebeaux et al. \[[@CR14]\]NANANANANANAFranceSequencing 16S rRNA geneNAPatient 1, 2012 (our study)M/49MyelomaYes (corticosteroid, immunosuppressive treatment with tacrolimus and lenalidomid)Skin abscess and ulcerated nodular lymphangitis on the left forearmTrimethoprim-Sulfamethoxazole---1 monthSkin trauma when gardeningFranceSequencing 16S rRNA geneRecoveryPatient 2, 2017 (our study)M/82MyastheniaDiabetesChronic kidney diseaseArterial hypertensionYes (corticosteroid, immunosuppressive treatment with azathioprin, diabetes, chronic kidney disease)Skin abscess and nodular lymphangitis on the right forearmAmoxicillin-clavulanic acid (1 g/t.id)---6 daysHand skin wound when gardeningFranceSequencing 16S rRNA geneRecovery*NA*not available

Study {#Sec2}
=====

Our study was performed in Nice Teaching Hospital, in Southeast France, during 1999--2019. A total of 50 isolates of *Nocardia* species were collected from 36 patients. The major types of infections were cutaneous infections (58%), pulmonary infections (33%) and bacteremia (9%). During the study period, all the isolates were identified to the species level using 16S rDNA gene sequencing as previously described \[[@CR8]\].

For the two *N. takedensis* strains isolated from patient 1 and patient 2, blast analysis of the 1435 nucleotides amplicon both showed 99.6% identity to the 16S rDNA sequence of *N. takedensis* CIP108681^T^. Phylogenetic positions of the two clinical strains within the genus *Nocardia* are shown in Fig. [1](#Fig1){ref-type="fig"}. The tree was obtained by neighbor-joining method using MEGA X software as previously described \[[@CR9]\]. The two isolates and *N. takedensis* CIP108681^T^ were compared using a random amplified polymorphic DNA-polymerase chain reaction (RAPD-PCR) with a coliphage M13 single stranded primer (5′-GAGGGTGGCGGCTCT-3). M13-PCR has been previously described by Guinebretière et al*.* for molecular typing of *Bacillus cereus* \[[@CR10]\]. In the present work, this method was used to obtain and compare the RAPD-PCR profiles of *N. takedensis* isolates. Antibiotic susceptibility testing was performed using E-Test strips (bioMérieux) and CLSI interpretative standards for *Nocardia* spp.\[[@CR11]\]. The two strains were sent to a French reference laboratory dedicated to *Nocardia* (French Observatory for Nocardiosis) to confirm AST results.Fig. 1Phylogenetic tree based on the 16S rDNA sequence of *Nocardia* strains isolated from patients 1 and 2. Phylogenetic positions of the *Nocardia* strains isolated from patient 1 and patient 2 within the genus *Nocardia* based on the 16S rDNA sequences. The tree was obtained by Neighbor-joining method using MEGA X software \[[@CR9]\]. Scale bar (= 0.01) indicates accumulated changes per nucleotide. The numbers next to the branches are the percentages determined in bootstrap analysis greater than 70% (1,000 replicates). The number in parentheses are the accession numbers of species in GenBank. *T* type strain,\*species not yet validly published

The first *N. takedensis* strain was isolated on November 19, 2012, from a 49 years-old male (patient 1) followed for a myeloma diagnosed in 2005. The patient had received allogeneic hematopoietic cell transplantation in 2008. In November 2012, he pricked his finger with a rose thorn while gardening at home without gloves in Fréjus (65 km from Nice). The patient attended the dermatology ward two weeks later, as a painful lesion had developed and spread from his hand to his left forearm. Physical examination by a dermatologist showed three inflammatory and painful ulcers distributed in a linear fashion, which suggested an ulcerated nodular lymphangitis with no regional adenopathy (Fig. [2](#Fig2){ref-type="fig"}). The body temperature was normal. The patient had an immunosuppressive therapy due to chronic GVHD (Graft-versus-host Disease) including prednisone 20 mg/day and tacrolimus, and for relapse of myeloma he received lenalidomid 15 mg/day and dexamethasone 40 mg/week. A bacterial (pyogenic bacteria, atypical mycobacteria, *Nocardia*) or fungal infection was suspected. Whole-body computed tomography (CT) scan was performed and a systemic invasive infection was ruled out. Biopsy samples of the lesions were sent for analysis and a presumptive antibiotic treatment by levofloxacin was initiated. Microscopic histological examination showed specific infection markers. Both Gram and Ziehl--Neelsen staining were negative. Chlorazol black fungal staining did not retrieve any mycelial filament. After 72 h, cultures on blood agar plates at 35 °C under 5% CO~2~ remained negative. The antibiotic treatment by levofloxacin was stopped after 3 days because of suspicion of Quinolone-induced Achilles tendinopathy. The dermatologist then switched the treatment to trimethoprim-sulfamethoxazole as he suspected a cutaneous Nocardiosis based on the first microbiological results (negativity of standard cultures after 72 h). Coletsos medium (Bio-Rad™, Marnes-la-Coquette, France) seeded for detection of atypical mycobacteria, grew *N. takedensis* under aerobic conditions at 30 °C in 4 days. The patient showed a rapid reduction of pain and cutaneous lesions within a week after the introduction of cotrimoxazole. He was considered cured after 1 month of treatment. Clinical and paraclinical long-term follow-up (every 2 weeks for multiple myeloma) excluded a late relapse of the nocardial infection.Fig. 2Ulcerated nodular lymphangitis of the left arm and forearm of patient 1. **a** Painful linear ulcerated nodules of the left arm and forearm (arrowhead) (on the first day of antibiotic treatment). **b** Healed lesions three weeks later

The second *N. takedensis* strain was isolated on November 24, 2017, from an 82-years-old immunocompromised male patient (patient 2) treated with prednisone 15 mg/day and azathioprine 150 mg/day for myasthenia since 2016. He was hospitalized in November 2017 to manage an acute ocular myasthenia with altered general conditions. Physical examination revealed a painless and non-itchy cutaneous abscess measuring 6 mm in diameter on the palmar face of his right hand with serous and hematic fluid, as well as a nodular lymphangitis on his right forearm. The body temperature was normal. A thorough interview of the patient revealed that this lesion had developed a few days before his admission, following a minimal hand skin wound when gardening at home without gloves in Menton (30 km from Nice). Laboratory investigations revealed an elevated C-reactive protein (CRP) at 55 mg/L. Whole-body CT scan excluded a systemic infection. Before starting the antibiotic treatment, a sterile swab was used to collect pus from the abscess. Gram staining did not show any microorganism. Swab cultures grew *N. takedensis* after 72 h of incubation both on blood agar plate (Oxoid, Dardilly, France) under aerobic atmosphere and on chocolate agar plate under 5% CO~2~. The patient was discharged with a prescription of amoxicillin-clavulanic acid 1 g t-i-d for 7 days. The wound completely healed 10 days after the beginning of this treatment. Long term hospital follow-up of this myasthenic patient (every two months) excluded a late relapse of the cutaneous Nocardiosis.

Both *N. takedensis* isolates displayed the same antimicrobial susceptibility pattern: susceptible to beta-lactams, trimethoprim-sulfamethoxazole, linezolid, amikacin, tobramycin and minocycline but resistant to ciprofloxacin and clarithromycin (Table [2](#Tab2){ref-type="table"}). To date, data concerning *N. takedensis* susceptibility to antibiotics are scarce. Only 8 isolates have been tested (including our study) and were susceptible to trimethoprim-sulfamethoxazole in vitro and 100% of the patients treated by an antibiotic treatment including trimethoprim-sulfamethoxazole completely recovered \[[@CR5], [@CR6], [@CR12], [@CR13]\]. Therefore, we assume that this molecule could be used as an empirical antibiotic therapy in case of cutaneous Nocardiosis due to *N. takedensis*, before an AST is available.Table 2Antimicrobial susceptibility testing determined using the E-test methodAntimicrobial agentStrain patient 1Strain patient 2MIC (µg/ml)Clinical categorization^a^MIC (µg/ml)Clinical categorization^a^Amikacin0.38S1SAmoxicillin-clavulanic acid6S6SCeftriaxone1.5S0.25SCiprofloxacin32R2IClarithromycin3R4RImipenem0.25S0.125SLinezolid1.5S0.19SMinocycline1S0.125STrimethoprim-sulfamethoxazole0.047S1STobramycin0.75S3S^a^Interpretations of MICs in terms of susceptibility for *Nocardia* according to the criteria of CLSI \[[@CR11]\].

The M13-PCR typing revealed that the two patients were infected by 2 different strains and excluded a clonal transmission between the 2 patients or a same origin of the strains. The two strains isolated in Southeast France were also different from the type strain *N. takedensis* CIP108681^T^ isolated in Japan (Fig. [3](#Fig3){ref-type="fig"}). *N. takedensis* was first characterized in 2005 by Yamamura et al. \[[@CR1]\]. The two first reference strains of *N. takedensis i.e.* MS1-3t and AS4-2 were isolated in Japan respectively from a moat sediment and from sludge obtained from a sewage treatment plant. To date, only nine clinical isolates of *N. takedensis* have been reported in human \[[@CR2]--[@CR7], [@CR13]--[@CR15]\]. The main clinical and microbiological features of *N. takedensis* isolates are summarized in the Table [1](#Tab1){ref-type="table"}. Including the two patients of our study, the mean patients' age was 64 years (33--87 years), with a sex ratio of 1.25. *N. takedensis* is mostly involved in primary cutaneous Nocardiosis, just as the closely related species *N. brasiliensis* is \[[@CR16], [@CR17]\]. Indeed, seven out of eight infected patients (88%) presented various forms of skin and soft tissue infections such as cellulitis, chronic skin ulceration, lymphangitis, or mycetoma, that occurred several days after a skin lesion allowing bacterial inoculation \[[@CR3]--[@CR7], [@CR15], our study\]. In one patient *N. takedensis* was isolated from a respiratory specimen but without any clinical or radiological signs of pulmonary Nocardiosis, therefore corresponding to a transient pulmonary colonization \[[@CR13]\]. For the last three clinical isolates reported in the literature, no clear and substantial data referring to the clinical cases were available \[[@CR2], [@CR14], [@CR15]\].Fig. 3Molecular typing using M13-PCR methods, as described by Guinebretière et al*.* \[[@CR10]\]. *Nocardia takedensis* strains isolated from the two patients and *Nocardia takedensis* CIP108681^T^

Collectively, these cases of primary cutaneous nocardiosis reported in US \[[@CR3]\], Mexico \[[@CR4]\], Asia \[[@CR5], [@CR6]\], and Europe \[[@CR7], our study\], during 2010--2017 support the idea of *N. takedensis* as a newly recognized pathogen involved in skin infections. An interesting hypothesis is that climatic and soil conditions could have play a role in the environmental spread of this bacterial species. Indeed, in most of the cases published in the literature, *N. takedensis* strains were isolated in geographical area with favorable climatic conditions (South--East France, Spain, Korea, Japon, Taiwan or Mexico) \[[@CR2], [@CR4]--[@CR7], [@CR13], our study\]. Moreover, Brown-Elliott et al., have previously suggested that *Nocardia brasiliensis*, a species that is phylogenetically closely related to *N. takedensis*, is predominantly isolated in tropical or subtropical region \[[@CR16]\]. Recently, Lebeaux et al., showed a higher density of *Nocardia* isolates in the South of France and overseas territories than in other French areas, suggesting that environmental conditions may also increase the spread of *Nocardia sp* \[[@CR14]\]. To date, data found in the literature concerning the potential impact of the climatic conditions on soil and on *N. takedensis* spreading are scarce and further studies will be necessary to assess this challenging hypothesis.

Concerning the source of contamination, it is likely possible that the two patients got infected by traumatic inoculation of *N. takedensis* present in the soil as both of them were gardening without gloves in the days preceding the onset of the symptoms. Furthermore, the two patients had received immunosuppressive drugs and corticosteroids which could have played a role in the infection. Immunosuppressive therapy or known risk factors of immunosuppression were found in all but one patient with *N. takedensis* infections (Table [1](#Tab1){ref-type="table"}).

Conclusions {#Sec3}
===========

With the spread of 16S rDNA sequencing, new *Nocardia* species have been recently described and the genus *Nocardia* currently encompasses more than 50 species involved in human diseases \[[@CR16]--[@CR18]\]. Besides, the rising number of patients receiving immunosuppressive therapies increases the risk of Nocardial infection through environmental exposure. Our study emphasizes the idea of *N. takedensis* as a newly recognized opportunistic pathogen responsible for skin infections. Infections occur after an inoculation following a cutaneous lesion. As this bacterium is found in the environment especially in soil, physicians should recommend their immunocompromised patients to wear shoes as well as clothing covering the skin when they are working in the soil (<https://www.cdc.gov/nocardiosis/prevention/index.html>). More, we would strongly recommend to immunocompromised patients to wear gloves when manipulating soil. This recommendation could also be extended to non-immunocompromised patient as primary cutaneous Nocardiosis has been repeatedly reported in this population. Lastly, because of the slow growth of *Nocardia* sp., prolonged culture conditions are required when a cutaneous Nocardiosis is suspected.
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